Research graph
References from Clinical Impact of Germline Pathogenic Variants in High-risk Prostate Cancer Treated with Radiotherapy. Local targets link to admitted publications; unresolved targets remain external evidence.
The lancet commission on prostate cancer: planning for the surge in cases
10.1016/s0140-6736(24)00651-2 · 2024 · External reference
Which patients with localized prostate cancer account for the greatest proportion of prostate cancer deaths?
10.1200/jco.2018.36.6_suppl.130 · 2018 · External reference
Transcriptomic heterogeneity of Gleason grade group 5 prostate cancer
10.1016/j.eururo.2020.05.009 · 2020 · External reference
Clinical applications of molecular biomarkers in prostate cancer
10.3390/cancers12061550 · 2020 · External reference
Molecular correlates of intermediate- and high-risk localized prostate cancer
10.1016/j.urolonc.2017.12.022 · 2018 · External reference
Inherited DNA-repair gene mutations in men with metastatic prostate cancer
10.1056/nejmoa1603144 · 2016 · External reference
Diagnosing hereditary cancer predisposition in men with prostate cancer
10.1038/s41436-020-0830-5 · 2020 · External reference
Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines
10.1001/jamaoncol.2018.6760 · 2019 · External reference
Germline genetic testing for inherited prostate cancer in practice: implications for genetic testing, precision therapy, and cascade testing
10.1002/pros.23739 · 2019 · External reference
Olaparib and Rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer
10.1080/14656566.2021.1912015 · 2021 · External reference
A three-stage genome-wide association study identifies a susceptibility locus for late radiotherapy toxicity at 2q24.1
10.1038/ng.3020 · 2014 · External reference
Unresolved reference
External reference
Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the association for molecular pathology
10.1038/gim.2015.30 · 2015 · External reference
Unresolved reference
External reference
Association of inherited mutations in DNA repair genes with localized prostate cancer
10.1016/j.eururo.2021.09.029 · 2022 · External reference
Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene
10.1086/345310 · 2003 · External reference
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
10.1038/bjc.2011.383 · 2011 · External reference
Rare germline variants in ATM predispose to prostate cancer: a PRACTICAL consortium study
10.1016/j.euo.2020.12.001 · 2021 · External reference
Germline sequencing analysis to inform clinical gene panel testing for aggressive prostate cancer
10.1001/jamaoncol.2023.3482 · 2023 · External reference
Assessing the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases
10.1038/s41467-025-56944-1 · 2025 · External reference
The influence of BRCA2 mutation on localized prostate cancer
10.1038/s41585-019-0164-8 · 2019 · External reference
Effect of BRCA mutations on metastatic relapse and cause-specific survival after radical treatment for localised prostate cancer
10.1016/j.eururo.2014.10.022 · 2015 · External reference
Olaparib for metastatic castration-resistant prostate cancer
10.1056/nejmoa1911440 · 2020 · External reference
PARP inhibitors combined with radiotherapy: are we ready?
10.3389/fphar.2023.1234973 · 2023 · External reference
CHEK2 is a multiorgan cancer susceptibility gene
10.1086/426403 · 2004 · External reference
Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants
10.1038/s41375-025-02635-1 · 2025 · External reference
Association of inherited pathogenic variants in checkpoint kinase 2 (CHEK2) with susceptibility to testicular germ cell tumors
10.1001/jamaoncol.2018.6477 · 2019 · External reference
Increased prevalence of germline pathogenic CHEK2 variants in individuals with pituitary adenomas
2024 · External reference
Pathogenic ATM mutations in cancer and a genetic basis for radiotherapeutic efficacy
10.1093/jnci/djaa095 · 2021 · External reference
Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM
10.18632/oncotarget.14400 · 2017 · External reference
